Senior Scientist, Bioanalytics
Sutro Biopharma
Summary
Sutro Biopharma is seeking a highly motivated and experienced Senior Bioanalytical Scientist to join its Preclinical Development team in South San Francisco, CA. The successful candidate will lead the design and execution of bioanalytical strategies for discovery, preclinical, and early clinical development programs. S/he will be responsible for developing and qualifying bioanalytical methods for small molecules and antibody-drug conjugates (ADCs), including drug-to-antibody ratio (DAR) assessment, and transferring these methods to CROs to enable preclinical and clinical studies. This role requires deep expertise in LC-MS/MS-based bioanalysis and a proven track record of independently driving complex programs in a fast-paced, collaborative environment.
Job description
Position Overview
Sutro Biopharma is seeking a highly motivated and experienced Senior Bioanalytical Scientist to join its Preclinical Development team in South San Francisco, CA. The successful candidate will lead the design and execution of bioanalytical strategies for discovery, preclinical, and early clinical development programs. S/he will be responsible for developing and qualifying bioanalytical methods for small molecules and antibody-drug conjugates (ADCs), including drug-to-antibody ratio (DAR) assessment, and transferring these methods to CROs to enable preclinical and clinical studies. This role requires deep expertise in LC-MS/MS-based bioanalysis and a proven track record of independently driving complex programs in a fast-paced, collaborative environment.
Responsibilities
- Lead and implement bioanalytical (BA) strategies to address key scientific questions across discovery, preclinical, and early clinical programs
- Develop stage-appropriate LC-MS/MS-based bioanalytical methods to quantify antibodies, ADCs, and small molecules in various biological matrices
- Transfer bioanalytical methods to CROs and serve as the primary scientific lead overseeing external studies
- Manage CRO relationships to ensure high-quality data delivery, adherence to timelines, and alignment with program goals
- Assess in vitro and in vivo drug-to-antibody ratio (DAR) stability using high-resolution mass spectrometry
- Analyze, interpret, and clearly communicate DMPK/BA data to internal project teams, senior leadership, and external collaborators
- Author high-quality DMPK/BA reports to support IND submissions, regulatory filings, patent applications, and publications
- Mentor and supervise junior bioanalytical scientists as needed
- Serve as a functional representative on cross-functional project teams, including partnered programs
- Contribute to the development of organizational processes, infrastructure, and resource planning, including capital equipment and budget considerations
Qualifications
- Ph.D. in PK/ADME, analytical chemistry, or a related field with 7+ years of relevant industry experience (biologics and small molecules)
- Exceptional candidates without a Ph.D. with 12+ years of relevant experience may be considered
- Proven track record of developing and optimizing quantitative bioanalytical methods for small molecules, biologics, and conjugates
- Strong expertise in LC-MS instrumentation, including triple quadrupole and high-resolution mass spectrometry
- Hands-on experience with ADC bioanalysis, including DAR characterization
- Demonstrated ability to independently establish new experimental protocols using novel methods or techniques
- Experience with ligand-binding assays is a plus
- Experience developing automated sample handling and assay workflows is preferred
- Familiarity with PK analysis and interpretation
- Working knowledge of regulatory guidance (FDA, ICH) relevant to bioanalytical and DMPK studies
- Experience with LIMS and common analytical/data processing software
- Demonstrated ability to author technical reports supporting regulatory filings, patents, and publications
- Excellent communication skills and ability to thrive in a collaborative, cross-functional environment
Requirements
- Ph.D. in PK/ADME, analytical chemistry, or a related field with 7+ years of relevant industry experience (biologics and small molecules)
- Exceptional candidates without a Ph.D. with 12+ years of relevant experience may be considered
- Proven track record of developing and optimizing quantitative bioanalytical methods for small molecules, biologics, and conjugates
- Strong expertise in LC-MS instrumentation, including triple quadrupole and high-resolution mass spectrometry
- Hands-on experience with ADC bioanalysis, including DAR characterization
- Demonstrated ability to independently establish new experimental protocols using novel methods or techniques
- Experience with ligand-binding assays is a plus
- Experience developing automated sample handling and assay workflows is preferred
- Familiarity with PK analysis and interpretation
- Working knowledge of regulatory guidance (FDA, ICH) relevant to bioanalytical and DMPK studies
- Experience with LIMS and common analytical/data processing software
- Demonstrated ability to author technical reports supporting regulatory filings, patents, and publications
- Excellent communication skills and ability to thrive in a collaborative, cross-functional environment
Benefits
- Bonus
- Equity
- Benefits
Company overview
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California, focused on clinical-stage drug discovery, development and manufacturing. Founded in 2003, the company leverages its proprietary cell-free protein synthesis platform, XpressCF+, to develop oncology therapeutics using protein engineering and rational design. Sutro specializes in antibody-drug conjugates (ADCs), including novel exatecan and dual-payload ADCs, with a mission to transform cancer treatment through precisely designed therapeutics. The company's technology enables rapid parallel expression of protein variants and precise incorporation of non-natural amino acids, allowing for the development of homogeneous site-specific ADCs. Sutro has established collaborations with major pharmaceutical companies including Astellas, Merck, and Vaxcyte, and maintains its own cGMP manufacturing facility. With approximately 290 employees, the company is advancing a robust early-stage pipeline while exploring innovative approaches to targeted oncology therapies that aim to provide broader patient benefit and improved patient experiences.